Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + trebananib
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + trebananib is a combination therapy consisting of paclitaxel, a microtubule-stabilizing chemotherapy agent, and trebananib, a peptibody that inhibits angiogenesis by preventing angiopoietin-1 and angiopoietin-2 from binding to Tie2 receptors. This combination has been investigated primarily for the treatment of various cancers, including ovarian cancer and breast cancer.
- Other names
- trebananib + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)
Beyond the preview
Go deeper on paclitaxel + trebananib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + trebananib.